13F-HR filed by Cutter Capital Management, LP
Cutter Capital Management, LP filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 25 holding rows worth $259,345,671.
- Accession
- 0001214659-24-009296
- Filer
- CIK 1983313
- Filed
- 2024-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2024
A holdings report, 25 entries on the cover page, a total value of $259,345,671 stated on the cover page (in dollars after the unit check, H1), rows summing to $259,345,671 with VALUE read as dollars as filed, 13F file number 028-23904. A later restatement replaced it, so the quarter does not use it. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | 110122108 | COM | 446,900 | $24,235,387 | dollars as filed | |
| Gilead Sciences,Inc. | 375558103 | COM | 265,436 | $19,443,187 | dollars as filed | |
| TEVA PHARMACEUTICAL INDS LTD SPONSORED ADS | 881624209 | ADR | 1,135,710 | $16,024,868 | dollars as filed | |
| REGENERON PHARMACEUTICALS COM | 75886F107 | Stock | 16,360 | $15,746,336 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 175,000 | $15,284,500 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 289,366 | $12,544,016 | dollars as filed | |
| ROYALTY PHARMA PLC | G7709Q104 | SHS CLASS A | 411,540 | $12,498,470 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 94,379 | $12,218,305 | dollars as filed | |
| ACADIA PHARMACEUTICALS INC | 004225108 | COM | 658,409 | $12,173,982 | dollars as filed | |
| BIOGEN INC COM | 09062X103 | Stock | 52,000 | $11,212,760 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 2,105,459 | $10,695,732 | dollars as filed | |
| HALOZYME THERAPEUTICS INC COM | 40637H109 | Stock | 255,049 | $10,375,393 | dollars as filed | |
| PERRIGO CO PLC SHS | G97822103 | Stock | 322,114 | $10,368,850 | dollars as filed | |
| EXELIXIS INC COM | 30161Q104 | Stock | 398,762 | $9,462,622 | dollars as filed | |
| AVADEL PHARMACEUTICALS PLC | G29687103 | COM SHS | 541,926 | $9,153,130 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 11,040 | $8,588,678 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 288,580 | $8,438,079 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 120,185 | $8,191,810 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 107,000 | $7,441,850 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 227,337 | $6,167,653 | dollars as filed | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 278,638 | $4,878,951 | dollars as filed | |
| LEGEND BIOTECH CORP | 52490G102 | SPONSORED ADS | 79,830 | $4,477,665 | dollars as filed | |
| KYVERNA THERAPEUTICS INC | 501976104 | COMMON STOCK | 166,514 | $4,136,208 | dollars as filed | |
| PLIANT THERAPEUTICS INC | 729139105 | COM | 194,119 | $2,892,373 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 157,964 | $2,694,866 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001214659-24-009296 | this filing | 2024-05-15 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001214659-24-013872 | base | 2024-08-06 | acceptance time not in the bulk data set |